



REASONS TO CONSIDER



High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.



Structural Tailwinds

The cost of genomic sequencing has dropped from nearly USD\$100mm per genome in 2002 to less than USD\$1,000 in 2020. Adoption has continued to rise, as costs plummet.¹



Targeted Exposure

CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

KEY INFORMATION

As of 31 October 2023


Exchange Code	CURE
IRESS	CURE.AXW
ISIN	AU0000028110
Issuer	Global X Management (AUS) Limited
Domicile	Australia
Base Currency	Australian Dollar
Currency Hedged	No
Inception Date	08 Nov 2018
Mgt. Fee (% p.a.)	0.45
Fund Size (\$mn)	31.7
NAV per Unit (\$)	35.82

PERFORMANCE (%)


Trailing Return*	1M	YTD	1Y	3Y	5Y	Since Inception	Calendar Year Return*	2022	2021	2020	2019	2018
CURE	-7.5%	-14.5%	-18.5%	-12.5%	-2.2%	-2.2%	CURE	-20.6%	-15.8%	33.6%	32.0%	-
Index	-7.7%	-14.4%	-18.4%	-12.2%	-1.2%	-1.8%	Index	-20.3%	-15.5%	34.8%	32.5%	-5.6%
S&P 500	-0.2%	18.1%	10.7%	13.4%	13.0%	12.9%	S&P 500	-12.6%	36.0%	7.3%	30.9%	5.6%

* Total returns in Australian dollar terms. Returns for periods greater than one year are annualised. Fund inception date 8 Nov 2018. Note that index and fund returns shown are 'net total return', meaning dividends are reinvested net of any withholding taxes across the entire index in proportion to prevailing index weights. Index returns are theoretical and do not include the impact of fees or costs of investing. Past performance is not a reliable indicator of future results.

INDUSTRY BREAKDOWN (%)



MARKET CAPITALISATION BREAKDOWN (%)





TOP 10 HOLDINGS (%) Holdings Subject to Change

Mirati Therapeutics Inc	2.2	Vertex Pharmaceuticals Inc	1.5
Apellis Pharmaceuticals Inc	1.7	Seagen Inc	1.5
Blueprint Medicines Corp	1.6	Gilead Sciences Inc	1.5
Immunovant Inc	1.6	Biohaven Ltd	1.5
Ionis Pharmaceuticals Inc	1.5	Neurocrine Biosciences Inc	1.4

INDEX DESCRIPTION

The S&P Biotechnology Select Industry Index tracks the performance of U.S. listed companies that are classified as belonging to the GICS biotechnology sub-industry and meet certain market capitalisation and liquidity requirements.

Constituents are equally weighted subject to liquidity and the index rebalances quarterly.

PORTFOLIO STATISTICS

Number of Holdings	133
Median Market Cap (\$bn)	1.8
P/E Ratio [^]	N/A
P/B Ratio [^]	3.9

DISTRIBUTION DETAILS

Distribution Frequency	Annually
Latest Distribution	\$0.02
Latest Distribution Date	30 Jun 2022
12-Month Yield (%)	N/A

BENCHMARK DETAILS

Name	S&P Biotechnology Select Industry Index
Base Currency	US Dollar
Rebalancing Frequency	Quarterly
Weighting Scheme	Modified Equal Weighted

[^] Weighted average of price divided by earnings (P/E) and book value (P/B) per share. N/A where P/E Ratio is negative.

¹ National Human Genome Research Institute, Nov 2021

The issuer of units in Global X S&P Biotech ETF (CURE) ARSN: 628 037 105 is the responsible entity of the Fund, being Global X Management (AUS) Limited (AFSL 466778) ("Global X"). The product disclosure statement (PDS) for the Fund contains all of the details of the offer of units in the Fund. Copies of the PDS are available from Global X Management (AUS) Limited or at www.globalxetfs.com.au. In respect of each retail product, Global X has prepared a target market determination (TMD) which describes the type of customers who the relevant retail product is likely to be appropriate for. The TMD also specifies distribution conditions and restrictions that will help ensure the relevant product is likely to reach customers in the target market. Each TMD is available at www.globalxetfs.com.au. The information provided in this document is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information in this document, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. None of Global X, the group of companies which Mirae Asset Global Investments Co., Ltd is the parent, or their respective directors, employees or agents guarantees the performance of any products issued by Global X or the repayment of capital or any particular rate of return therefrom. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance. Standard & Poor's S&P Indices are trademarks of Standard & Poor's Financial Services LLC. "S&P", as used in the term S&P 500, is a trademark of Standard & Poor's Financial Services LLC ("S&P") respectively and has been licensed for use by Global X. Global X products are not sponsored, endorsed, sold or promoted by S&P, and S&P does not make any representation regarding the advisability of investing in ETFs products.